Condition: Herpes Zoster · Sponsor: Peking University Third Hospital
This multicenter RCT aims to compare the efficacy and safety of Brivudine versus Famciclovir in treating acute herpes zoster. Primary objective: Evaluate pain reduction via Numeric Pain Rating Scale (NPRS) at Day 30. Secondary objectives: Compare NPRS at Day 3/Day 7/Day 14/Day 90, time to lesion resolution, Postherpetic Neuralgia (PHN) incidence, and safety.
This description comes directly from the study's public registry record.
Jin-Zhu Guo, M.D. · 008613521115717 · guojinzhu_826@163.com
Always discuss trial participation with your own doctor first.
| Peking University Third Hospital | Beijing, China | Recruiting |
| Beijing Hospital of Traditional Chinese Medicine, Capital Medical University | Beijing, China | Recruiting |
| Peking University First Hospital | Beijing, China | Recruiting |
| Xuanwu Hospital, Capital Medical University | Beijing, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07099157